Clinical trial · Observational
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
NCT06369935CI-TRIAL-00076140not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Equecabtagene Autoleucel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Best Overall Response Rate， BOR
- timeFrame
- up to 24 weeks
- description
- Patients treatmented with Equecabtagene Autoleucel, the optimal disease state evaluated by the researcher is strict complete response (sCR),complete response (CR), very good partial response (Very Good Partial Response (VGPR) or partial response (partial response,PR) rate.
Secondary outcomes (5)
- measure
- PFS rate of 6 month
- timeFrame
- up to 24 weeks
- description
- Probability of patients not experiencing disease progression or death from any cause 6 months after starting treatment with equecabtagene autoleucel
- measure
- OS rate of 6 month
- timeFrame
- up to 24 weeks
- description
- Probability of patient survival 6 months after equecabtagene autoleucel treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with confirmed relapsed/refractory multiple myeloma; * Based on clinical practice, the physician decided to administer equecabtagene autoleucel treatment; * Voluntarily sign the informed consent form approved by the ethics committee. Exclusion Criteria: * Patients who are hypersensitive to the active ingredients of the product or any excipients (dimethyl sulfoxide, compound electrolyte injection, human albumin); * The researcher believes that patients are unable to return for follow-up visits or that it is impossible to complete the study; * Patients with expected survival less than 3 months
References
Publications (0)
Data not yet available
No reference posted for this study.